Cargando…

Comparison of Prognostic Genomic Predictors in Colorectal Cancer

BACKGROUND: Although several prognostic genomic predictors have been identified from independent studies, it remains unclear whether these predictors are actually concordant with respect to their predictions for individual patients and which predictor performs best. We compared five prognostic genom...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yun-Yong, Lee, Sung Sook, Lim, Jae Yun, Kim, Sang Cheol, Kim, Sang Bae, Sohn, Bo Hwa, Chu, In-Sun, Oh, Sang Cheul, Park, Eun Sung, Jeong, Woojin, Kim, Sung Soo, Kopetz, Scott, Lee, Ju-Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634034/
https://www.ncbi.nlm.nih.gov/pubmed/23626670
http://dx.doi.org/10.1371/journal.pone.0060778
Descripción
Sumario:BACKGROUND: Although several prognostic genomic predictors have been identified from independent studies, it remains unclear whether these predictors are actually concordant with respect to their predictions for individual patients and which predictor performs best. We compared five prognostic genomic predictors, the V7RHS, the ColoGuideEx, the Meta163, the OncoDX, and the MDA114, in terms of predicting disease-free survival in two independent cohorts of patients with colorectal cancer. STUDY DESIGN: Using original classification algorithms, we tested the predictions of five genomic predictors for disease-free survival in two cohorts of patients with colorectal cancer (n = 229 and n = 168) and evaluated concordance of predictors in predicting outcomes for individual patients. RESULTS: We found that only two predictors, OncoDX and MDA114, demonstrated robust performance in identifying patients with poor prognosis in 2 independent cohorts. These two predictors also had modest but significant concordance of predicted outcome (r>0.3, P<0.001 in both cohorts). CONCLUSIONS: Further validation of developed genomic predictors is necessary. Despite the limited number of genes shared by OncoDX and MDA114, individual-patient outcomes predicted by these two predictors were significantly concordant.